According to the letter, the violations were related to Globus Medical’s (GMED) Class II Excelsius GPS (EGPS) surgical robot and the associated interbody spine and cranial modules. The FDA noted ...

Globus Medical Inc. (NYSE:GMED) shares have reached an unprecedented peak, touching an all-time high of $93.68. With a market capitalization of $12.7 billion and an impressive revenue growth of ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

The acquisition of Nevro further expands Globus Medical's presence in the musculoskeletal market, unlocking a $2.5 billion market opportunity. This strategic move positions Globus to further add to ...

In the preceding three months, 5 analysts have released ratings for Globus Medical GMED, presenting a wide array of perspectives from bullish to bearish. The table below summarizes their recent ...